TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To assess the tolerability and effect of a probiotic product, when co-administered with antibiotics, on the incidence and duration of loose/watery stools following the antibiotic treatment in children.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Kefir; Type: EXPERIMENTAL; Interventions: Other: Kefir | Intervention Type: OTHER; Name: Kefir; Assigned to Arm(s): Kefir | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: BB-12; Type: EXPERIMENTAL; Interventions: Biological: Bifidobacterium animalis subsp. lactis BB-12 | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Control | Intervention Type: BIOLOGICAL; Name: Bifidobacterium animalis subsp. lactis BB-12; Assigned to Arm(s): BB-12 | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
C: Arm Label: Probiotics; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Probiotic capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo capsules | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic capsules; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo capsules; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lactobacillus GG | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus GG; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Technology-Enhanced Peer Navigation to Improve IDUs' Engagement in HIV Care: The mPeer2Peer Study
Brief Summary: The purpose of the mPeer2Peer Study (mP2P) is to see if we can use a smartphone and a Peer Navigator (PN) to improve medical care for HIV-positive people who have been out of HIV care for over one year.


Options:
A: Arm Label: Standard HIV Care Arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Peer Navigation Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Peer Navigation Arm | Intervention Type: BEHAVIORAL; Name: Peer Navigation Arm; Assigned to Arm(s): Peer Navigation Arm
B: Arm Label: Standard IPV Assessment; Type: EXPERIMENTAL; Interventions: Behavioral: Standard IPV Assessment | Arm Label: Standard DOVE intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Standard IPV Assessment, Behavioral: Standard DOVE Intervention | Intervention Type: BEHAVIORAL; Name: Standard IPV Assessment; Assigned to Arm(s): Standard DOVE intervention, Standard IPV Assessment | Intervention Type: BEHAVIORAL; Name: Standard DOVE Intervention; Assigned to Arm(s): Standard DOVE intervention
C: Arm Label: Infants at risk; Type: N/A; Interventions: Behavioral: ProAsk | Arm Label: Infants not at risk; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ProAsk; Assigned to Arm(s): Infants at risk
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Community Health Workers; Type: EXPERIMENTAL; Interventions: Behavioral: community health workers | Intervention Type: BEHAVIORAL; Name: community health workers; Assigned to Arm(s): Community Health Workers

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Novel Treatments for Alcohol Dependence: A Randomized Controlled Trial of Structured Stepped-care Intervention for Psychiatric Comorbidity
Brief Summary: There is a high rate of psychological comorbidity in people suffering from alcohol dependence. There is a need for an effective integrated treatment for alcohol dependence and comorbid anxiety or depression. This study will test the efficacy of a novel integrated intervention for comorbid alcohol dependence and anxiety or mood disorder.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Contingency Management | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Non Contingent Control Condition | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Non Contingent Control Condition; Assigned to Arm(s): 2
B: Arm Label: Integrated care; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Integrated care; Assigned to Arm(s): Integrated care | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care
C: Arm Label: CBT-AD; Type: EXPERIMENTAL; Interventions: Behavioral: CBT-AD | Arm Label: ETAU; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ETAU | Intervention Type: BEHAVIORAL; Name: CBT-AD; Assigned to Arm(s): CBT-AD | Intervention Type: BEHAVIORAL; Name: ETAU; Assigned to Arm(s): ETAU
D: Arm Label: Positive psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Positive Psychotherapy for smoking cessation, Drug: Nicotine polacrilex, Behavioral: Behavioral smoking cessation treatment | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine polacrilex, Behavioral: Relaxation training, Behavioral: Behavioral smoking cessation treatment | Intervention Type: BEHAVIORAL; Name: Positive Psychotherapy for smoking cessation; Assigned to Arm(s): Positive psychotherapy | Intervention Type: DRUG; Name: Nicotine polacrilex; Assigned to Arm(s): Positive psychotherapy, Standard treatment | Intervention Type: BEHAVIORAL; Name: Relaxation training; Assigned to Arm(s): Standard treatment | Intervention Type: BEHAVIORAL; Name: Behavioral smoking cessation treatment; Assigned to Arm(s): Positive psychotherapy, Standard treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CIDRZ 1229- Better Health Outcomes Through Mentoring and Assessment (BHOMA)
Brief Summary: BHOMA Interventions

The purpose of this study is to assess the impact of the BHOMA intervention on health in 3 rural districts of Zambia.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: BHOMA; Type: EXPERIMENTAL; Interventions: Other: BHOMA | Intervention Type: OTHER; Name: BHOMA; Assigned to Arm(s): BHOMA
B: Arm Label: All practices; Type: OTHER; Interventions: Behavioral: DQIP Intervention | Intervention Type: BEHAVIORAL; Name: DQIP Intervention; Assigned to Arm(s): All practices
C: Arm Label: Weekly SMS, brief message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Daily SMS, Brief message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Daily SMS, Long Message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Weekly SMS, Long Message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Intervention Type: BEHAVIORAL; Name: Short Message Services to Support ARV therapy adherence; Assigned to Arm(s): Control Group, Daily SMS, Brief message, Daily SMS, Long Message, Weekly SMS, Long Message, Weekly SMS, brief message
D: Arm Label: Intervention group; Type: N/A; Interventions: Other: e-Chasqui | Arm Label: Simultaneous/historical control group; Type: N/A; Interventions: N/A | Intervention Type: OTHER; Name: e-Chasqui; Assigned to Arm(s): Intervention group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Etude de l'Effet du dropéridol et de l'Ondansetron Sur l'Incidence de l'Akathisie Post opératoire en Chirurgie Ambulatoire
Brief Summary: The main objective of this study is to evaluate the incidence of akathisia with Droperidol, the prophylactic treatment of post operative nausea and vomiting, used at two different doses, versus control group (Ondansetron), in outpatient surgery.The primary endpoint is to compare the number of observed akathisia (Barnes score \> 1) in the Droperidol arms (0,625 mg and 1,25 mg) versus Ondansetron 4 hours after recovery from anesthesia.The assumption is that there is a greater risk of akathisia among patients taking Droperidol in prevention of NPVO, that among patients taking Ondansetron.


Options:
A: Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone, Drug: Morphine, Drug: Zofran, Drug: Paracetamol, Drug: Ibuprofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Drug: Morphine, Drug: Zofran, Drug: Paracetamol, Drug: Ibuprofen | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Dexamethasone, Placebo | Intervention Type: DRUG; Name: Zofran; Assigned to Arm(s): Dexamethasone, Placebo | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Dexamethasone, Placebo | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Dexamethasone, Placebo
B: Arm Label: Dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Ondansetron; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ondansetron | Arm Label: Granisetron; Type: ACTIVE_COMPARATOR; Interventions: Drug: Granisetron | Intervention Type: DRUG; Name: Ondansetron; Assigned to Arm(s): Ondansetron | Intervention Type: DRUG; Name: Granisetron; Assigned to Arm(s): Granisetron
D: Arm Label: Arm 1 : Droperidol 1,25 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration | Arm Label: Arm 2 : Droperidol 0,625 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration | Arm Label: Arm 3 : Odansetron 4 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration | Intervention Type: DRUG; Name: Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration; Assigned to Arm(s): Arm 1 : Droperidol 1,25 mg, Arm 2 : Droperidol 0,625 mg, Arm 3 : Odansetron 4 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Automated Adjustment of Inspired Oxygen on Fluctuations of Regional Cerebral and Arterial Oxygenation in Preterm Infants With Frequent Desaturations
Brief Summary: In this study the investigators test the hypothesis that automated FiO2 adjustment increases the time of brain tissue oxygenation within the intended reference range. Furthermore, the investigators studied the change in workload during automated FiO2 adjustment as compared to manual adjustment by the nursing staff.


Options:
A: Arm Label: CLiO2; Type: EXPERIMENTAL; Interventions: Device: Automated oxygen control by the CLiO2 algorithm | Arm Label: Oxygenie; Type: EXPERIMENTAL; Interventions: Device: Automated oxygen control by the Oxygenie algorithm | Intervention Type: DEVICE; Name: Automated oxygen control by the CLiO2 algorithm; Assigned to Arm(s): CLiO2 | Intervention Type: DEVICE; Name: Automated oxygen control by the Oxygenie algorithm; Assigned to Arm(s): Oxygenie
B: Arm Label: Automatic Oxygen Control; Type: EXPERIMENTAL; Interventions: Device: Automatic Oxygen control | Arm Label: Manual oxygen control; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual Oxygen Control | Intervention Type: DEVICE; Name: Automatic Oxygen control; Assigned to Arm(s): Automatic Oxygen Control | Intervention Type: OTHER; Name: Manual Oxygen Control; Assigned to Arm(s): Manual oxygen control
C: Arm Label: RFM visible; Type: EXPERIMENTAL; Interventions: Device: New Life Box Respiratory Function Monitor | Arm Label: RFM masked; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: New Life Box Respiratory Function Monitor; Assigned to Arm(s): RFM visible
D: Arm Label: Automated FiO2 control; Type: EXPERIMENTAL; Interventions: Device: Automated FiO2 Control | Arm Label: Manual Adjustment; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DEVICE; Name: Automated FiO2 Control; Assigned to Arm(s): Automated FiO2 control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy
Brief Summary: Funding Source- FDA OOPD

The purpose of this study is to investigate the safety and efficacy of clenbuterol on motor function in individuals with late-onset Pompe disease (LOPD) who are treated with enzyme replacement therapy (ERT).


Options:
A: Arm Label: Alglucosidase Alfa/Alglucosidase Alfa; Type: EXPERIMENTAL; Interventions: Biological: alglucosidase alfa | Arm Label: Placebo/Alglucosidase Alfa; Type: EXPERIMENTAL; Interventions: Biological: alglucosidase alfa | Intervention Type: BIOLOGICAL; Name: alglucosidase alfa; Assigned to Arm(s): Alglucosidase Alfa/Alglucosidase Alfa, Placebo/Alglucosidase Alfa
B: Arm Label: alglucosidase alfa; Type: ACTIVE_COMPARATOR; Interventions: Biological: alglucosidase alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: alglucosidase alfa; Assigned to Arm(s): alglucosidase alfa | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Clenbuterol; Type: EXPERIMENTAL; Interventions: Drug: Clenbuterol | Arm Label: Placebo Comparator; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Clenbuterol; Assigned to Arm(s): Clenbuterol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator
D: Arm Label: avalglucosidase alfa (GZ402666); Type: EXPERIMENTAL; Interventions: Drug: Avalglucosidase alfa (GZ402666) | Arm Label: alglucosidase alfa (GZ419829); Type: ACTIVE_COMPARATOR; Interventions: Drug: Alglucosidase alfa (GZ419829) | Intervention Type: DRUG; Name: Avalglucosidase alfa (GZ402666); Assigned to Arm(s): avalglucosidase alfa (GZ402666) | Intervention Type: DRUG; Name: Alglucosidase alfa (GZ419829); Assigned to Arm(s): alglucosidase alfa (GZ419829)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Study Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms in Postmenopausal Women With an Intact Uterus
Brief Summary: This study will be a prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter trial of postmenopausal subjects with an intact uterus.


Options:
A: Arm Label: Vagifem; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vagifem, Other: Placebo gel | Arm Label: Replens; Type: ACTIVE_COMPARATOR; Interventions: Device: Replens, Other: Placebo tablet | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo tablet, Other: Placebo gel | Intervention Type: DRUG; Name: Vagifem; Assigned to Arm(s): Vagifem | Intervention Type: DEVICE; Name: Replens; Assigned to Arm(s): Replens | Intervention Type: OTHER; Name: Placebo tablet; Assigned to Arm(s): Placebo, Replens | Intervention Type: OTHER; Name: Placebo gel; Assigned to Arm(s): Placebo, Vagifem
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SCE-B, Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: SCE-B, Drug: Placebo | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SCE-B; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1, 2, 3
C: Arm Label: Treatment 1; Type: EXPERIMENTAL; Interventions: Drug: Estradiol, Drug: Progesterone, Drug: Placebo | Arm Label: Treatment 2; Type: EXPERIMENTAL; Interventions: Drug: Estradiol, Drug: Progesterone, Drug: Placebo | Arm Label: Treatment 3; Type: EXPERIMENTAL; Interventions: Drug: Estradiol, Drug: Progesterone, Drug: Placebo | Arm Label: Treatment 4; Type: EXPERIMENTAL; Interventions: Drug: Estradiol, Drug: Progesterone, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Estradiol; Assigned to Arm(s): Treatment 1, Treatment 2, Treatment 3, Treatment 4 | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Treatment 1, Treatment 2, Treatment 3, Treatment 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Treatment 1, Treatment 2, Treatment 3, Treatment 4
D: Arm Label: Tibolone; Type: ACTIVE_COMPARATOR; Interventions: Drug: tibolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tibolone; Assigned to Arm(s): Tibolone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the WiiFit to Enhance Walking in Older Adults With Lower Limb Amputation
Brief Summary: WiiNWALK is a 4 week physical activity, with the intervention of a WiiFit, targeted to improve walking capacity in individuals with either a unilateral below-knee or above-knee amputation. This is a randomized control trial to evaluate the effectiveness of the WiiNWALK program in older (50+ years) community living adults with lower limb amputations (LLA).

Hypothesis: We expect the WiiNWALK intervention will have a treatment effect with improvement in functional walking capacity, compared to the control group who will only be playing cognitive games. Secondarily, a functional walking capacity will also include an improvement in lower extremity strength and balance, inter-limb gait symmetry, balance confidence along with participation in daily and social activities, locomotor capabilities and an increase in physical activities.


Options:
A: Arm Label: Cognitive Games; Type: ACTIVE_COMPARATOR; Interventions: Device: Wii Big Brain Academy Degree program | Arm Label: WiiNWALK Intervention; Type: EXPERIMENTAL; Interventions: Device: Nintendo Wii | Intervention Type: DEVICE; Name: Nintendo Wii; Assigned to Arm(s): WiiNWALK Intervention | Intervention Type: DEVICE; Name: Wii Big Brain Academy Degree program; Assigned to Arm(s): Cognitive Games
B: Arm Label: Early PABC Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Behavior Change (PABC) | Arm Label: Wait-List Control Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Behavior Change (PABC) | Intervention Type: BEHAVIORAL; Name: Physical Activity Behavior Change (PABC); Assigned to Arm(s): Early PABC Intervention, Wait-List Control Intervention | Intervention Type: BEHAVIORAL; Name: Physical Activity Behavior Change (PABC); Assigned to Arm(s): Early PABC Intervention, Wait-List Control Intervention
C: Arm Label: Error-augmentation training; Type: EXPERIMENTAL; Interventions: Behavioral: Error-augmentation gait training | Arm Label: Error-correction training; Type: EXPERIMENTAL; Interventions: Behavioral: Error-correction gait training | Arm Label: Supervised waking; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised walking | Intervention Type: BEHAVIORAL; Name: Error-augmentation gait training; Assigned to Arm(s): Error-augmentation training | Intervention Type: BEHAVIORAL; Name: Error-correction gait training; Assigned to Arm(s): Error-correction training | Intervention Type: BEHAVIORAL; Name: Supervised walking; Assigned to Arm(s): Supervised waking
D: Arm Label: Physio Therapy; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: Virtual Reality; Type: EXPERIMENTAL; Interventions: Other: Exercise | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Physio Therapy, Virtual Reality

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects and Costs of a Day Care Centre Program Designed for People With Dementia - a 24 Month Controlled Study
Brief Summary: Attending day care centres with programs specifically designed for patients with dementia is believed to postpone admittance to nursing home as well as increase quality of life and well-being for both patients and their family caregivers. We aim to investigate to what degree attendance in day care centres with programs for people with dementia is effective for patient and their caregivers whilst also cost efficient for society. The study consists of a quasi-experimental trial with comparison group. 400 patients with dementia, along with a family caregiver, will be included in the trial. Effects will be measured at baseline, after one and two years. Data collection will be made at three levels; at patient level with measures of cognition, depression, quality of life, functioning in activities in daily living, neuropsychiatric symptoms and death; at caregiver level with measures of depression, level of burden and quality of life; and at societal level with measures of nursing home admittance, hospital stays and use of other health resources. Additionally,a qualitative interview study will include 20 dyads from the main trial. The main focus will be on how attending day care centre programs for patients with dementia affect the lives of both patients and caregivers. Five of these dyads will be followed closely throughout the participation period to be used as case examples.


Options:
A: Arm Label: Day care for patients with dementia; Type: EXPERIMENTAL; Interventions: Behavioral: Day care for patients with dementia | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Day care for patients with dementia; Assigned to Arm(s): Day care for patients with dementia
B: Arm Label: Tailored Activity Program; Type: EXPERIMENTAL; Interventions: Other: Tailored Activity Program | Arm Label: Attention Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Attention Control | Intervention Type: OTHER; Name: Tailored Activity Program; Assigned to Arm(s): Tailored Activity Program | Intervention Type: OTHER; Name: Attention Control; Assigned to Arm(s): Attention Control
C: Arm Label: intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: maintaining of occupational therapy | Arm Label: control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: maintaining of occupational therapy; Assigned to Arm(s): intervention arm
D: Intervention Type: BEHAVIORAL; Name: community occupational therapy in dementia; Assigned to Arm(s): N/A

Answer: A